0001193125-24-134793.txt : 20240509 0001193125-24-134793.hdr.sgml : 20240509 20240509080534 ACCESSION NUMBER: 0001193125-24-134793 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240509 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240509 DATE AS OF CHANGE: 20240509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Phathom Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001783183 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 824151574 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39094 FILM NUMBER: 24928690 BUSINESS ADDRESS: STREET 1: 100 CAMPUS DRIVE, STREET 2: SUITE 102 CITY: FLORHAM PARK STATE: NJ ZIP: 07932 BUSINESS PHONE: (877) 742-8466 MAIL ADDRESS: STREET 1: 100 CAMPUS DRIVE, STREET 2: SUITE 102 CITY: FLORHAM PARK STATE: NJ ZIP: 07932 8-K 1 d837391d8k.htm 8-K 8-K
false 0001783183 0001783183 2024-05-09 2024-05-09

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 9, 2024

 

 

PHATHOM PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39094   82-4151574
(State or other jurisdiction of
incorporation or organization)		   (Commission
File Number)		   (I.R.S. Employer
Identification No.)

100 Campus Drive, Suite 102

Florham Park, New Jersey 07932

(Address of principal executive offices) (Zip Code)

(877) 742-8466

(Registrant’s telephone number, include area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, par value $0.0001 per share   PHAT   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 

Item 2.02 Results of Operations and Financial Condition.

On May 9, 2024, Phathom Pharmaceuticals, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
No.		   

Description

99.1    Press Release issued on May 9, 2024
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    PHATHOM PHARMACEUTICALS, INC.
Date: May 9, 2024     By:  

/s/ Molly Henderson

      Molly Henderson
      Chief Financial and Business Officer
 EX-99.1 2 d837391dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

 

  •  

Over 17,500 total prescriptions for VOQUEZNA® products have been dispensed, launch-to-date, a 361% increase since last quarterly report

 

  •  

Net revenues of $1.9 million reported for the first full quarter of launch

 

  •  

Cigna Healthcare recently added VOQUEZNA tablets to its formularies, broadening coverage to approximately 48% of all U.S. commercial lives

 

  •  

National direct-to-consumer campaign, “VOQUEZNA Can Kick Some Acid,” underway across broadcast and streaming TV

 

  •  

Management to host conference call today, May 9, 2024, at 8:30 a.m. ET

FLORHAM PARK, N.J., May 9, 2024 — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today reported financial results for the first quarter of 2024, and provided recent business highlights.

“Phathom is quickly establishing VOQUEZNA as the first and only FDA-approved treatment of its kind for Erosive GERD and we are thrilled with the promising strides made in our first full quarter post-launch,” said Terrie Curran, President and CEO of Phathom. “We’re pleased that prescribers are embracing VOQUEZNA as a powerful new treatment option and that demand is rapidly growing. The positive feedback from both physicians and patients, and the impact our medicines are making on the lives of those suffering from acid-related GI diseases, continues to inspire our team. With our dedicated national sales force engaging thousands of prescribers daily, and a compelling direct-to-consumer campaign underway, VOQUEZNA brand awareness is also building. We expect both overall demand and total dispensed prescriptions to increase in the coming months as the launch progresses, formulary coverage broadens, and, if approved, VOQUEZNA’s label expands to include the treatment associated with symptomatic heartburn for Non-Erosive GERD.”

Recent Business Highlights and First Quarter 2024 Results:

VOQUEZNA® Launch Progress:

 

  •  

Phathom’s commercial launch continues to build momentum and demonstrate strong physician and patient demand for VOQUEZNA. Total estimated prescription demand for VOQUEZNA tablets, VOQUEZNA Triple Pak, and VOQUEZNA Dual Pak now exceeds 43,000 prescriptions written, launch to date. Total prescription demand represents the cumulative number of prescriptions that have been written, regardless of whether the prescription has been filled or dispensed. As of April 26, 2024, over 17,500 prescriptions for VOQUEZNA products have been filled through retail pharmacies and BlinkRx. The VOQUEZNA prescriber base also continues to expand with filled prescriptions generated by more than 3,800 unique prescribers, representing over 215% growth since the company’s last quarterly report.

 

  •  

Phathom continues to make important progress securing broad commercial coverage for VOQUEZNA. As of May 1, 2024, Cigna Healthcare has added VOQUEZNA tablets to its formularies for its over 9 million commercial customers. Approximately 72 million commercially covered lives in the United States now have access to VOQUEZNA tablets, comprising an estimated 48% of total U.S. commercial lives. Negotiations with other large payers are progressing and Phathom expects to secure additional commercial coverage for its products throughout 2024.

  •  

In March 2024, Phathom launched its new broadcast ad and full-scale, direct-to-consumer (DTC) campaign, “VOQUEZNA Can Kick Some Acid,” to raise awareness of its powerful first-in-class Erosive GERD treatment and encourage people to speak to their doctor about VOQUEZNA. The DTC campaign first aired on streaming platforms including Hulu, Prime Video, and Peacock and as of late-April, has begun airing on traditional broadcast and cable television. The campaign is also featured on consumer-facing platforms across Facebook, Instagram, waiting room TVs in doctor offices, and digital banner ads. Phathom anticipates this campaign will reach the millions of Erosive GERD sufferers and motivate these patients to seek a new class of treatment that works differently than proton pump inhibitors (PPIs).

Recent Business and Regulatory Highlights:

 

  •  

Phathom is planning a robust presence at Digestive Disease Week® (DDW) 2024, being held May 18-21 in Washington, D.C. This marks Phathom’s first major medical meeting with a branded presence for VOQUEZNA tablets, including sponsorship of a live product theater presentation highlighting VOQUEZNA tablets as the first and only FDA-approved treatment of its kind for Erosive GERD. In addition, clinical data updates will be shared, including the first oral presentation of the Phase 3 PHALCON-NERD-301 trial results, investigating VOQUEZNA as a daily treatment in Non-Erosive Reflux Disease (NERD).

 

  •  

Phathom’s New Drug Application (NDA) for VOQUEZNA as a daily treatment of heartburn associated with symptomatic Non-Erosive GERD in adults remains under review by the U.S. Food and Drug Administration (FDA) with an assigned Prescription Drug User Fee Act (PDUFA) target action date of July 19, 2024. If approved, Phathom expects to launch VOQUEZNA for this expanded indication immediately.

 

  •  

Phathom anticipates the initiation of a Phase 3 Non-Erosive GERD trial later this year to investigate As Needed dosing of VOQUEZNA for active heartburn episodes, a dosing regimen for which PPIs are not approved in the U.S.

 

  •  

Phathom’s planned Phase 2 study to investigate VOQUEZNA as a potential treatment for Eosinophilic Esophagitis (EoE) in adults and adolescents remains on track to begin later this year.

First Quarter Financial Results:

 

  •  

Revenue: Net revenues for the first quarter 2024 were $1.9 million related to sales of VOQUEZNA, VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK. There were no revenues for the first quarter 2023 due to the launch of VOQUEZNA during the fourth quarter 2023.

 

  •  

Research and development (R&D) expenses: R&D expenses for the first quarter 2024 were $9.4 million, a decrease of $2.1 million compared to $11.5 million for the first quarter 2023. The decrease was a result of decreased clinical trial expenses due to the winddown of activities related to the PHALCON-NERD-301 study and lower chemistry manufacturing and controls activity.

 

  •  

Selling, general and administrative (SG&A) expenses: SG&A expenses for the first quarter 2024 were $62.0 million, an increase of $43.4 million compared to $18.6 million for the first quarter 2023. The increase was a result of higher personnel costs and increased activity related to the ongoing buildout of commercial infrastructure and marketing activity in support of the launch of VOQUEZNA products.

  •  

Net loss: Net loss for the first quarter 2024 was $82.9 million, compared to $37.8 million for the first quarter 2023. First quarter 2024 net loss included a non-cash charge related to stock-based compensation of $5.6 million compared to $7.0 million for first quarter 2023. Non-GAAP adjusted net loss for the first quarter 2024 was $64.8 million compared to $25.1 million for the same period in 2023. These non-GAAP adjusted net losses, more fully described below under “Non-GAAP Financial Measures,” exclude non-cash stock-based compensation charges, non-cash interest expense related to the accounting for our revenue interest financing liability, which are in excess of the actual interest owed, and interest expense related to the amortization of debt discount on our term loan. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the tables below.

 

  •  

Cash and cash equivalents: As of March 31, 2024, cash and cash equivalents were $322.2 million. Up to an additional $150 million is also available under the Company’s term loan with Hercules.

 

  •  

Cash runway: Based on its current cash resources and operating plan, including expected product revenues, and the funds potentially available under its existing term loan, the Company believes it will have sufficient capital to fund operations through the end of 2026.

Conference Call and Webcast

Phathom will host a conference call and webcast to discuss its first quarter financial results and business highlights today, May 9, 2024, at 8:30 a.m. ET. A live webcast will be available on the investors page of Phathom’s website under Events & Presentations. A replay of the webcast will be available following the completion of the event and will be archived for up to 90 days.

Non-GAAP Financial Measures

This press release includes financial results prepared in accordance with accounting principles generally accepted in the United States (GAAP), and also certain non-GAAP financial measures. In particular, Phathom has provided non-GAAP adjusted net loss and adjusted net loss per share, adjusted to exclude the items below. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. However, Phathom believes the presentation of non-GAAP adjusted net loss and adjusted net loss per share, when viewed in conjunction with GAAP results, provides investors with a more meaningful understanding of ongoing operating performance. These measures exclude (i) non-cash stock-based compensation, which is substantially dependent on changes in the market price of common shares, (ii) interest expense related to the accounting for our revenue interest financing liability, which are in excess of the actual interest owed, and (iii) interest expense related to the amortization of debt discount on our term loan.

Phathom believes the presentation of these non-GAAP financial measures provides useful information to management and investors regarding Phathom’s results of operations. When GAAP financial measures are viewed in conjunction with these non-GAAP financial measures, investors are provided with a more meaningful understanding of Phathom’s ongoing operating performance and are better able to compare Phathom’s performance between periods. In addition, these non-GAAP financial measures are among those indicators Phathom uses as a basis for evaluating performance, and planning and forecasting future periods. These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. A reconciliation between these non-GAAP measures and the most directly comparable GAAP measures is provided later in this press release.

About Phathom Pharmaceuticals, Inc. Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) and currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the treatment of Erosive GERD and relief of heartburn associated with Erosive GERD in adults, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.

Forward-Looking Statements

This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about the timing of regulatory review and potential commercial launch of vonoprazan as a daily treatment for Non-Erosive GERD, the timing of commencement of the Phase 3 As Needed dosing Non-Erosive GERD and Phase 2 EoE trials, the availability of additional funds under our term loan agreement, future growth in demand and our ability to secure additional commercial coverage for our products, and our cash runway. The inclusion of forward-looking statements should not be regarded as a representation by Phathom that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Phathom’s business, including, without limitation: we may not be able to successfully commercialize VOQUEZNA, VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, which will depend on a number of factors including coverage and reimbursement levels from governmental authorities and health insurers as well as market acceptance by healthcare providers; we may use our capital resources sooner than expected, or our operating plan may overestimate our expected product revenues, which could require us to reduce expenses or raise additional capital sooner than expected; the inherent risks of clinical development of vonoprazan; Phathom’s dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; regulatory developments in the United States and foreign countries; unexpected adverse side effects or inadequate efficacy of vonoprazan that may limit its development, regulatory approval and/or commercialization, or may result in recalls or product liability claims; Phathom’s ability to obtain and maintain intellectual property protection and non-patent regulatory exclusivity for vonoprazan; and other risks described in the Company’s prior press releases and the Company’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Phathom undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

MEDIA CONTACT

Nick Benedetto

1-877-742-8466

media@phathompharma.com

INVESTOR CONTACT

Eric Sciorilli

1-877-742-8466

ir@phathompharma.com

Selected Condensed Balance Sheets

(in thousands)

(unaudited)

 

     March 31,
2024		     December 31,
2023		  

Assets

     

Cash and cash equivalents

    $ 322,229     $ 381,393  

Total assets

    $ 356,499     $ 413,842  

Total liabilities

    $ 505,002     $ 486,601  

Total stockholders’ deficit

    $ (148,503 )    $ (72,759 ) 

Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

(unaudited)

 

     Three Months Ended
March 31,		  
     2024     2023  

Product revenue, net

    $ 1,912     $ —   

Cost of revenue

      426       —   
  

 

 

    

 

 

  

Gross profit

      1,486       —   

Operating expenses:

     

Research and development

      9,430       11,479  

Selling, general and administrative

      62,010       18,598  
  

 

 

    

 

 

  

Total operating expenses

      71,440       30,077  
  

 

 

    

 

 

  

Loss from operations

      (69,954 )      (30,077 ) 

Other income (expense):

     

Interest income

      4,313       1,460  

Interest expense

      (17,168 )      (9,217 ) 

Other (expense) income, net

      (43 )      20  
  

 

 

    

 

 

  

Total other expense

      (12,898 )      (7,737 ) 
  

 

 

    

 

 

  

Net loss and comprehensive loss

    $ (82,852 )    $ (37,814 ) 
  

 

 

    

 

 

  

Net loss per share, basic and diluted

    $ (1.42 )    $ (0.89 ) 
  

 

 

    

 

 

  

Reconciliation of GAAP to Non-GAAP Financial Measures

(in thousands, except share and per share amounts)

(unaudited)

 

     Three months ended
March 31,		  
     2024     2023  

Reconciliation of GAAP to Non-GAAP adjusted net loss:

     

GAAP net loss

    ($ 82,852 )    ($ 37,814 ) 

Stock-based compensation expense (A)

      5,626       7,048  

Non-cash interest on revenue interest financing liability

      11,956       5,154  

Interest expense related to amortization of debt discount

      474       496  
  

 

 

    

 

 

  

Non-GAAP adjusted net loss

    ($ 64,796 )    ($ 25,116 ) 

Reconciliation of GAAP to Non-GAAP adjusted net loss per share — basic and diluted:

     

GAAP net loss per share — basic and diluted

    ($ 1.42 )    ($ 0.89 ) 

Stock-based compensation expense (A)

      0.10       0.17  

Non-cash interest on revenue interest financing liability

      0.20       0.12  

Interest expense related to amortization of debt discount

      0.01       0.01  
  

 

 

    

 

 

  

Non-GAAP net loss per share — basic and diluted

    ($ 1.11 )    ($ 0.59 ) 
  

 

 

    

 

 

  

Weighted-average shares of common stock outstanding, basic and diluted

      58,371,480       42,354,520  

 

(A)

Stock-based compensation consists of the following:

 

                                                     
     Three months ended
March 31,		  
     2024      2023  

Research and development

      1,249        1,776  

Selling, general and administrative

      4,377        5,272  

###

EX-101.SCH 3 phat-20240509.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 phat-20240509_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 phat-20240509_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Document and Entity Information
May 09, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001783183
Document Type 8-K
Document Period End Date May 09, 2024
Entity Registrant Name PHATHOM PHARMACEUTICALS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-39094
Entity Tax Identification Number 82-4151574
Entity Address, Address Line One 100 Campus Drive
Entity Address, Address Line Two Suite 102
Entity Address, City or Town Florham Park
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07932
City Area Code (877)
Local Phone Number 742-8466
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol PHAT
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.phathompharma.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d837391d8k.htm phat-20240509.xsd phat-20240509_lab.xml phat-20240509_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d837391d8k.htm": { "nsprefix": "phat", "nsuri": "http://www.phathompharma.com/20240509", "dts": { "inline": { "local": [ "d837391d8k.htm" ] }, "schema": { "local": [ "phat-20240509.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "phat-20240509_lab.xml" ] }, "presentationLink": { "local": [ "phat-20240509_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://www.phathompharma.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-05-09_to_2024-05-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d837391d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-05-09_to_2024-05-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d837391d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.phathompharma.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.phathompharma.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.phathompharma.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.phathompharma.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.phathompharma.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.phathompharma.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.phathompharma.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.phathompharma.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.phathompharma.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.phathompharma.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.phathompharma.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.phathompharma.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.phathompharma.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.phathompharma.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.phathompharma.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.phathompharma.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.phathompharma.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.phathompharma.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.phathompharma.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.phathompharma.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.phathompharma.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.phathompharma.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.phathompharma.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.phathompharma.com//20240509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001193125-24-134793-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-134793-xbrl.zip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d837391d8k_htm.xml IDEA: XBRL DOCUMENT 0001783183 2024-05-09 2024-05-09 false 0001783183 8-K 2024-05-09 PHATHOM PHARMACEUTICALS, INC. DE 001-39094 82-4151574 100 Campus Drive Suite 102 Florham Park NJ 07932 (877) 742-8466 false false false false Common Stock, par value $0.0001 per share PHAT NASDAQ true true